OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY

被引：0
|
作者：
Young, LeAnne [1 ]
Finnigan, Shanda [2 ]
Streicher, Howard [2 ]
Chen, Helen [2 ]
Murray, James [2 ]
Sen, H. Nida [1 ]
Sharon, Elad [2 ]
机构：
[1] NEI, Cleveland, OH USA
[2] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
644
引用
收藏
页码：A386 / A387
页数：2
相关论文
共 50 条
  • [31] Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
    Liu, Lei
    Lan, Pengpeng
    Wu, Guiping
    Zhu, Xiaojie
    Shi, Hongfeng
    Li, Yan
    Li, Ruili
    Zhao, Ling
    Xu, Juan
    Xu, Min
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [32] Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
    Mudassar, Faiqa
    Shen, Han
    Cook, Kristina M.
    Hau, Eric
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2022, 66 (04) : 560 - 574
  • [33] Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1
    Li, Z-F
    Chen, C.
    Zeng, J-Y
    Wang, S.
    Han, S-Q
    Zhang, Y-Q
    Qiu, D-D
    Guo, H-X
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (11) : 3997 - 4004
  • [34] Clinical significance and therapeutic potential of programmed death 1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
    Grimm, M.
    Gasser, M.
    Koenigshausen, M.
    Stein, C.
    Lutz, J.
    Krol, S.
    Nichiporuk, E.
    Thiede, A.
    Heemann, U.
    Waaga-Gasser, A. M.
    ONKOLOGIE, 2008, 31 : 80 - 80
  • [35] Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
    Schalper, Kurt A.
    Venur, Vyshak Alva
    Velcheti, Vamsidhar
    JOURNAL OF RECEPTOR LIGAND AND CHANNEL RESEARCH, 2015, 8 : 1 - 7
  • [36] Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma
    Tamura, Akihiro
    Yoshida, Makiko
    Yamamoto, Nobuyuki
    Nino, Nanako
    Nakatani, Naoko
    Ichikawa, Takayuki
    Nakamura, Sayaka
    Saito, Atsuro
    Kozaki, Aiko
    Kishimoto, Kenji
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    BLOOD, 2018, 132
  • [37] Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
    Zhang, Ying
    Zhu, Weipei
    Zhang, Xueguang
    Qu, Qiuxia
    Zhang, Liyuan
    ONCOLOGY LETTERS, 2017, 14 (06) : 7225 - 7231
  • [38] Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo
    Zhang, Rui
    Lyu, Cuicui
    Lu, Wenyi
    Pu, Yedi
    Jiang, Yanyu
    Deng, Qi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2800 - 2812
  • [39] Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
    Chen, Zhifang
    Pang, Nannan
    Du, Rong
    Zhu, Yuejie
    Fan, Lingling
    Cai, Donghui
    Ding, Yan
    Ding, Jianbing
    MEDIATORS OF INFLAMMATION, 2016, 2016
  • [40] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Chen, Daniel S.
    Irving, Bryan A.
    Hodi, F. Stephen
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6580 - 6587
12345